EvoEndo

Executive Summary

EvoEndo is a Pittsburgh-based medical device company that has developed the EvoEndo® Single-Use Endoscopy System, an FDA-cleared platform designed for sedation-free transnasal and transoral endoscopy in patients of all ages. The system addresses significant unmet needs in gastrointestinal endoscopy by eliminating the risks, costs, and logistical burdens associated with sedation. Its single-use design also reduces cross-contamination risk and enables procedures in non-traditional settings such as physician offices, potentially expanding access to screening and diagnostic endoscopy. The initial target market includes upper GI procedures, with plans to expand into lower GI and pediatric populations. The company's value proposition centers on improved patient experience, lower per-procedure costs, and the ability to perform endoscopies without anesthesia support. This could be particularly impactful for colorectal cancer screening and for patients who cannot tolerate sedation. EvoEndo faces competition from traditional reusable endoscopes and other single-use systems, but its differentiated sedation-free approach may capture a niche in outpatient and office-based settings. Commercial traction, reimbursement coverage, and clinical evidence from ongoing studies will be key to adoption. Overall, EvoEndo is well-positioned to disrupt the standard of care in endoscopy if it can demonstrate clinical and economic advantages at scale.

Upcoming Catalysts (preview)

• Q2 2027CMS Reimbursement Determination for Sedation-Free Endoscopy55% success
• Q4 2026Publication of Pivotal Clinical Study Results in Pediatric Population70% success
• Q3 2026Key Partnership with National Hospital System for Adoption65% success